23572198|t|(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study.
23572198|a|OBJECTIVES: Little is known regarding the 'false-negative' or 'false-positive' striatal dopamine transporter binding on SPECT for the diagnosis of dementia with Lewy bodies (DLB). We explored the clinical course in patients fulfilling the criteria for clinical DLB with a normal ((123)I)FP-CIT SPECT (ie, SPECT scan negative, clinical features positive (S-CF+)) and patients not fulfilling DLB criteria with an abnormal scan (S+CF-). DESIGN: Longitudinal case study over 2-5 years. SETTING: Consecutive referrals of patients with mild dementia to dementia clinics in western Norway. PARTICIPANTS: 50 patients (27 men and 23 women; mean age at baseline of 74 (range 52-88)) with ((123)I)FP-CIT SPECT images underwent cluster analysis: 20/50 patients allocated to a 'DLB' and 8 to a 'non-DLB' cluster were included. OUTCOME MEASURES: Scores on standardised clinical rating scales for hallucinations, parkinsonism, fluctuations, rapid eye movement (REM) sleep behaviour disorder and visually rated ((123)I)FP-CIT SPECT. RESULTS: During the follow-up period, in the S+CF- group (n=7), frequency and severity of DLB symptoms tended to increase, particularly parkinsonism (7/7) and cognitive fluctuations (7/7), while severity of visual hallucinations and REM sleep behaviour disorder remained stable. The S-CF+ (n=3) fulfilled the operationalised criteria for probable DLB both at baseline and at the end of the follow-up. CONCLUSIONS: The findings suggest that systematic visual analyses of ((123)I)FP-CIT SPECT can detect people with DLB prior to the development of the full clinical syndrome. In addition, the study indicates that some patients fulfilling clinical criteria for probable DLB have a normal scan, and further studies are required to characterise these patients better.
23572198	6	12	FP-CIT	Chemical	MESH:C087552
23572198	32	57	dementia with Lewy bodies	Disease	MESH:D020961
23572198	174	194	dopamine transporter	Gene	6531
23572198	233	258	dementia with Lewy bodies	Disease	MESH:D020961
23572198	260	263	DLB	Disease	MESH:D020961
23572198	301	309	patients	Species	9606
23572198	347	350	DLB	Disease	MESH:D020961
23572198	366	372	(123)I	Chemical	MESH:C000614958
23572198	373	379	FP-CIT	Chemical	MESH:C087552
23572198	452	460	patients	Species	9606
23572198	476	479	DLB	Disease	MESH:D020961
23572198	602	610	patients	Species	9606
23572198	621	629	dementia	Disease	MESH:D003704
23572198	633	641	dementia	Disease	MESH:D003704
23572198	686	694	patients	Species	9606
23572198	699	702	men	Species	9606
23572198	710	715	women	Species	9606
23572198	765	771	(123)I	Chemical	MESH:C000614958
23572198	772	778	FP-CIT	Chemical	MESH:C087552
23572198	826	834	patients	Species	9606
23572198	851	854	DLB	Disease	MESH:D020961
23572198	872	875	DLB	Disease	MESH:D020961
23572198	968	982	hallucinations	Disease	MESH:D006212
23572198	984	996	parkinsonism	Disease	MESH:D010302
23572198	1012	1061	rapid eye movement (REM) sleep behaviour disorder	Disease	MESH:D020187
23572198	1082	1088	(123)I	Chemical	MESH:C000614958
23572198	1089	1095	FP-CIT	Chemical	MESH:C087552
23572198	1193	1196	DLB	Disease	MESH:D020961
23572198	1239	1251	parkinsonism	Disease	MESH:D010302
23572198	1262	1284	cognitive fluctuations	Disease	MESH:D003072
23572198	1310	1331	visual hallucinations	Disease	MESH:D006212
23572198	1336	1364	REM sleep behaviour disorder	Disease	MESH:D020187
23572198	1450	1453	DLB	Disease	MESH:D020961
23572198	1574	1580	(123)I	Chemical	MESH:C000614958
23572198	1581	1587	FP-CIT	Chemical	MESH:C087552
23572198	1617	1620	DLB	Disease	MESH:D020961
23572198	1720	1728	patients	Species	9606
23572198	1771	1774	DLB	Disease	MESH:D020961
23572198	1850	1858	patients	Species	9606
23572198	Association	MESH:C087552	MESH:D020961
23572198	Association	MESH:D020961	6531

